Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-FGFR1, BMS-986036 Vector   (CAT#: GTVCR-WQ784MR)

This product GTVCR-WQ784MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting FGFR1. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Homo sapiens
RefSeq NM_001174063.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-FGFR1, BMS-986036 Vector (GTVCR-WQ784MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1761MR IVTScrip™ pSP6-VEE-mRNA-Anti-APP, LY3002813 Vector Vector LY3002813
GTVCR-WQ364MR IVTScrip™ pT7-VEE-mRNA-Anti-CGRP, ALD-403 Vector Vector ALD-403
GTVCR-WQ1087MR IVTScrip™ pT7-VEE-mRNA-Anti-S, CT-P-59 Vector Vector CT-P-59
GTVCR-WQ2215MR IVTScrip™ pT7-VEE-mRNA-Anti-PCSK9, PF-05335810 Vector Vector PF-05335810
GTVCR-WQ1182MR IVTScrip™ pSP6-VEE-mRNA-Anti-EGFR, Fab C225 Vector Vector Fab C225
GTVCR-WQ682MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL23A, BI 655066 Vector Vector BI 655066
GTVCR-WQ2412MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL2RA, RO 24-7375 Vector Vector RO 24-7375
GTVCR-WQ573MR IVTScrip™ pSP6-VEE-mRNA-Anti-Canlupfam CD52, AT-005 Vector Vector AT-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW